OTC Watch

All stocks / AURX

Nuo Therapeutics, Inc. AURX

Nuo Therapeutics (AURX): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBTexas, USA
Live quote on OTC Markets

Market listing

Full name
NUO THERAPEUTICS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 08:30 · News Release
Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-08-17 08:00 · News Release
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 17:15 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($2,512,216)
What it means

It spends more than it earns

Under strain

The company lost $2.5 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$548,946
Net cash used in operating activities
($864,971)
What it means

The cash could run out soon

Under strain

It had $548,946 in the bank and used about $72,081 a month. At that pace the money lasts about 8 months unless it borrows or sells more shares.

The report says
Total assets
$1,845,662
Total liabilities
$2,802,221
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $1.8 million. Its debts and unpaid bills add up to $2.8 million. That is about $1.52 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-12

Estimated float about 40,833,853 shares as of 2026-11-12: 48,585,593 outstanding minus 7,751,740 held by 4 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
48.2M
2026-03-26
48.3M
2026-03-31
48.3M
2026-05-12
48.4M
2026-06-30
48.4M
2026-08-12
48.4M
2026-09-30
48.6M
2026-11-12
48.6M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-QFORM 10-Q
2026-10-06 8-KFORM 8-K
2026-10-06 4FORM 4 - SCOTT PITTMAN - SECOND FUNDING WARRANTS
2026-08-31 4/AFORM 4/A
2026-08-28 4FORM 4
2026-08-17 8-KFORM 8-K
2026-08-14 10-QFORM 10-Q
2026-07-02 4FORM 4
2026-07-02 4FORM 4
2026-07-02 4FORM 4
2026-07-02 4FORM 4
2026-07-02 4FORM 4

Common questions about AURX

Does AURX file reports with the SEC?

Yes. Nuo Therapeutics files with the SEC under company number 0001091596. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many AURX shares are outstanding?

48,585,593 shares as of 2026-11-12, as reported to the SEC.

Source record

Has AURX filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Nuo Therapeutics?

Officers named in its insider filings: Peter Clausen (CSO/COO) and David Emerson Jorden (CEO/CFO).

Source record

Is Nuo Therapeutics making money?

The company lost $2.5 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record